Oral Propanolol for Surgically Inaccessible Cavernous Malformations

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Cavernous Malformations,Cerebral and/or Spinal

In brief

The purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.

Key facts

Study ID

NCT03523650

Run by

University of Virginia

People needed

346

Starts

2018-02-07

Expected to finish

2019-01-01

Last updated by the study team

2018-05-14

Who can join

Age: 1 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of isolated or familial cavernous malformation syndrome:
• symptomatic cavernous malformation not amenable to surgical resection.
• familial cavernous malformation with seizure, other neurological symptom or surgically inaccessible lesion.
• Written and informed consent obtained prior to study enrollment.
• Subject is able and willing to return for outpatient visits.
• Negative pregnancy test at time of enrollment for women and child-bearing potential.

You may not qualify if…

• Age less than 1 year-old.
• Propranolol allergy or allergy to other b-blockers.
• Estimated life expectancy of less than 1 year.
• History of severe anemia, cardiac dysfunction, or diabetes.
• A psychiatric or substance abuse problem that may interfere with study compliance.
• Pregnant and lactating women.

Where it is running

• Univeristy of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.